glp 1 agonists for type 2 diabetes GLP-1 receptor in the treatment of – state-of-the-art Glucagon-like peptide 1(GLP-1) receptor agonists

Phospholipid peroxide accumulation depletes intracellular COQ10 and GSH on the one hand while increasing cellular vulnerability to ferroptosis on the other

(2011) found that Epitalon could restore disrupted circadian rhythms in elderly people, suggesting potential applications in sleep disorders and other conditions related to circadian rhythm disruption

Clinical trials evaluated AOD-9604 for durations ranging from single doses to 24 weeks of continuous daily administration

The MOXI randomized trial did not show improved live birth or semen outcomes with one antioxidant combination, and the large SUMMER trial published in 2025 similarly found no significant improvement in ongoing pregnancy rates with the tested antioxidant supplement versus placebo